Timothy A. Dotson is a leading expert in pharmaceutical development and regulatory affairs, with 25+ years of multi-disciplinary experience. He has spent a large part of his career in the animal health industry, involved with pharmaceutical R&D, veterinary drug and pesticide regulations, and state and federal compliance.  He has regulatory experience with generic animal drugs, veterinary devices, animal supplements and probiotics, Minor Use-Minor Species (MUMS) applications, OTC animal drugs, GRAS Notices, New Animal Drug Applications (NADAs), and other related FDA initiatives.  While at Merial Limited, Tim was responsible for the FRONTLINE and HEARTGARD brand line of products, and helped achieve FDA approval for NEXGARD (afoxolaner) Chewables for Dogs.

 

Tim served as Chair of the Animal Drug Section (ADS) of the leading animal health trade association, the Animal Health Institute (AHI), and in various other capacities within AHI such as Chair of the Labeling Working Group. 

 

Prior to consulting, he worked for Merial Limited, Jaguar Animal Health, Kindred Biosciences, UCB Chemicals Corporation, and Technical Assessment Systems, Inc. 

 

Tim holds a Master of Science degree in Toxicology from The American University and a Bachelor of Science degree in Microbiology from Virginia Polytechnic Institute and State University.

 

For more information, visit https://www.linkedin.com/in/tadotson/